Price T Rowe Associates Inc Genmab A/S Transaction History

Price T Rowe Associates Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$27.94 - $35.44 $313,682 - $397,884	-11,227 Reduced 5.59%	189,491 $6.03 Million
Q3 2023 Nov 14, 2023	SELL	$35.27 - $42.24 $1.78 Million - $2.13 Million	-50,380 Reduced 20.06%	200,718 $7.08 Million
Q4 2022 Feb 14, 2023	SELL	$33.8 - $47.06 $37,180 - $51,766	-1,100 Reduced 0.44%	251,098 $10.6 Million
Q2 2022 Aug 15, 2022	SELL	$26.83 - $38.57 $33.2 Million - $47.7 Million	-1,235,837 Reduced 83.05%	252,198 $8.19 Million
Q1 2022 May 16, 2022	SELL	$30.95 - $39.68 $6.65 Million - $8.53 Million	-214,996 Reduced 12.62%	1,488,035 $53.8 Million
Q4 2021 Feb 14, 2022	SELL	$35.87 - $47.12 $3.82 Million - $5.02 Million	-106,547 Reduced 5.89%	1,703,031 $67.4 Million
Q3 2021 Nov 15, 2021	SELL	$41.55 - $48.72 $7.6 Million - $8.91 Million	-182,863 Reduced 9.18%	1,809,578 $79.1 Million
Q2 2021 Aug 16, 2021	BUY	$32.88 - $44.57 $1.29 Million - $1.75 Million	39,357 Added 2.02%	1,992,441 $81.4 Million
Q1 2021 May 17, 2021	BUY	$30.92 - $44.4 $47.5 Million - $68.2 Million	1,536,846 Added 369.22%	1,953,084 $64.1 Million
Q4 2020 Feb 16, 2021	BUY	$33.66 - $40.76 $14 Million - $17 Million	416,238 New	416,238 $16.9 Million

236

52.5M

10.2K

25.5K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13.6B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

Stay updated on Price T Rowe Associates Inc with notifications on news.